A EARLY SAFETY DATA FROM A RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PHASE 2B STUDY OF IGV-001, AN AUTOLOGOUS CELL IMMUNOTHERAPY, VERSUS PLACEBO, IN NEWLY DIAGNOSED GLIOBLASTOMA

Authors

• Christopher Farrell

Publication/Presentation Date

10-2024

Volume

26

Issue

5

First Page

67

Last Page

68

Published In/Presented At

https://doi.org/10.1093/neuonc/noae144.222

Disciplines

Medicine and Health Sciences

Department(s)

Department of Surgery

Document Type

Article